Computational Identification and Binding Analysis of Orphan Human Cytochrome P450 4X1 Enzyme with Substrates

Overview

Journal BMC Res Notes

Publisher Biomed Central

Specialties Biology
General Medicine

Date 2015 Jan 18

PMID 25595103

Citations 8

Authors

Suresh Kumar

Affiliations

Soon will be listed here.

Abstract

Background: Cytochrome P450s (CYPs) are important heme-containing proteins, well known for their monooxygenase reaction. The human cytochrome P450 4X1 (CYP4X1) is categorized as "orphan" CYP because of its unknown function. In recent studies it is found that this enzyme is expressed in neurovascular functions of the brain. Also, various studies have found the expression and activity of orphan human cytochrome P450 4X1 in cancer. It is found to be a potential drug target for cancer therapy. However, three-dimensional structure, the active site topology and substrate specificity of CYP4X1 remain unclear.

Methods: In the present study, the three-dimensional structure of orphan human cytochrome P450 4X1 was generated by homology modeling using Modeller 9v8. The generated structure was accessed for geometrical errors and energy stability using PROCHECK, VERFIY 3D and PROSA. A molecular docking analysis was carried out against substrates arachidonic acid and anandamide and the docked substrates were predicted for drug-likeness, ADME-Tox parameters and biological spectrum activity.

Results: The three-dimensional model of orphan human cytochrome P450 4X1 was generated and assessed with various structural validation programmes. Docking of orphan human cytochrome P450 4X1 with arachidonic acid revealed that TYR 112, ALA 126, ILE 222, ILE 223, THR 312, LEU 315, ALA 316, ASP 319, THR 320, PHE 491 and ILE 492 residues were actively participating in the interaction, while docking of CYP4X1 with anandamide showed that TYR 112, GLN 114, PRO 118, ALA 126, ILE 222, ILE 223, SER 251, LEU 315, ALA 316 and PHE 491 key residues were involved in strong interaction.

Conclusion: From this study, several key residues were identified to be responsible for the binding of arachidonic acid and anandamide with orphan human cytochrome P450 4X1. Both substrates obeyed Lipinski rule of five in drug-likeness test and biological spectrum prediction showed anticarcinogenic activity. Compared to anandamide, arachidonic acid showed strong interaction with cytochrome P450 4X1 and also less health effect in certain human system in ADME-Tox prediction. These findings provide useful information on the biological role and structure-based drug design of orphan human cytochrome P450 4X1.

Citing Articles

CYP4X1 Expression Is Associated with Metastasis and Poor Prognosis in Patients with Colorectal Cancer.

Kim S, Kim H, Hong I, Lee M, Kim H, Kwak H Int J Mol Sci. 2025; 26(5).

PMID: 40076494 PMC: 11899201. DOI: 10.3390/ijms26051867.

Antimicrobial resistance in Klebsiella pneumoniae: identification of bacterial DNA adenine methyltransferase as a novel drug target from hypothetical proteins using subtractive genomics.

Omeershffudin U, Kumar S Genomics Inform. 2023; 20(4):e47.

PMID: 36617654 PMC: 9847377. DOI: 10.5808/gi.22067.

Human Orphan Cytochromes P450: An Update.

Molina-Ortiz D, Torres-Zarate C, Santes-Palacios R Curr Drug Metab. 2022; 23(12):942-963.

PMID: 36503398 DOI: 10.2174/1389200224666221209153032.

Role of Genetic Variation in Cytochromes P450 in Breast Cancer Prognosis and Therapy Response.

Hlavac V, Vaclavikova R, Brynychova V, Ostasov P, Kozevnikovova R, Kopeckova K Int J Mol Sci. 2021; 22(6).

PMID: 33802237 PMC: 8001203. DOI: 10.3390/ijms22062826.

Identification of biomarkers predicting the chemotherapeutic outcomes of capecitabine and oxaliplatin in patients with gastric cancer.

Zhang Y, Yuan Z, Shen R, Jiang Y, Xu W, Gu M Oncol Lett. 2020; 20(6):290.

PMID: 33029206 PMC: 7530885. DOI: 10.3892/ol.2020.12153.

References

Guengerich F, Cheng Q . Orphans in the human cytochrome P450 superfamily: approaches to discovering functions and relevance in pharmacology. Pharmacol Rev. 2011; 63(3):684-99. PMC: 3141877. DOI: 10.1124/pr.110.003525. View

Krieger E, Koraimann G, Vriend G . Increasing the precision of comparative models with YASARA NOVA--a self-parameterizing force field. Proteins. 2002; 47(3):393-402. DOI: 10.1002/prot.10104. View

Freitas M . MIA-QSAR modelling of anti-HIV-1 activities of some 2-amino-6-arylsulfonylbenzonitriles and their thio and sulfinyl congeners. Org Biomol Chem. 2006; 4(6):1154-9. DOI: 10.1039/b516396j. View

Guengerich F, Wu Z, Bartleson C . Function of human cytochrome P450s: characterization of the orphans. Biochem Biophys Res Commun. 2005; 338(1):465-9. DOI: 10.1016/j.bbrc.2005.08.079. View

Battista N, Fezza F, Maccarrone M . Endocannabinoids and their involvement in the neurovascular system. Curr Neurovasc Res. 2005; 1(2):129-40. DOI: 10.2174/1567202043480107. View

Guengerich F, Tang Z, Salamanca-Pinzon S, Cheng Q . Characterizing proteins of unknown function: orphan cytochrome p450 enzymes as a paradigm. Mol Interv. 2010; 10(3):153-63. PMC: 2895278. DOI: 10.1124/mi.10.3.6. View

Benkert P, Tosatto S, Schomburg D . QMEAN: A comprehensive scoring function for model quality assessment. Proteins. 2007; 71(1):261-77. DOI: 10.1002/prot.21715. View

Morris G, Huey R, Lindstrom W, Sanner M, Belew R, Goodsell D . AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009; 30(16):2785-91. PMC: 2760638. DOI: 10.1002/jcc.21256. View

Anzali S, Barnickel G, Cezanne B, Krug M, Filimonov D, Poroikov V . Discriminating between drugs and nondrugs by prediction of activity spectra for substances (PASS). J Med Chem. 2001; 44(15):2432-7. DOI: 10.1021/jm0010670. View

10.

Kumar S . Comparative modeling and molecular docking of orphan human CYP4V2 protein with fatty acid substrates: Insights into substrate specificity. Bioinformation. 2012; 7(7):360-5. PMC: 3280491. DOI: 10.6026/97320630007360. View

11.

Lipinski C . Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol. 2014; 1(4):337-41. DOI: 10.1016/j.ddtec.2004.11.007. View

12.

Bylund J, Zhang C, Harder D . Identification of a novel cytochrome P450, CYP4X1, with unique localization specific to the brain. Biochem Biophys Res Commun. 2002; 296(3):677-84. DOI: 10.1016/s0006-291x(02)00918-x. View

13.

Glaser F, Pupko T, Paz I, Bell R, Martz E, Ben-Tal N . ConSurf: identification of functional regions in proteins by surface-mapping of phylogenetic information. Bioinformatics. 2002; 19(1):163-4. DOI: 10.1093/bioinformatics/19.1.163. View

14.

Denisov I, Makris T, Sligar S, Schlichting I . Structure and chemistry of cytochrome P450. Chem Rev. 2005; 105(6):2253-77. DOI: 10.1021/cr0307143. View

15.

Castrignano T, DOnorio De Meo P, Cozzetto D, Talamo I, Tramontano A . The PMDB Protein Model Database. Nucleic Acids Res. 2005; 34(Database issue):D306-9. PMC: 1347467. DOI: 10.1093/nar/gkj105. View

16.

Savas U, Hsu M, Griffin K, Bell D, Johnson E . Conditional regulation of the human CYP4X1 and CYP4Z1 genes. Arch Biochem Biophys. 2005; 436(2):377-85. DOI: 10.1016/j.abb.2005.02.022. View

17.

Capdevila J, Falck J . Biochemical and molecular properties of the cytochrome P450 arachidonic acid monooxygenases. Prostaglandins Other Lipid Mediat. 2002; 68-69:325-44. DOI: 10.1016/s0090-6980(02)00038-2. View

18.

Sievers F, Wilm A, Dineen D, Gibson T, Karplus K, Li W . Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol. 2011; 7:539. PMC: 3261699. DOI: 10.1038/msb.2011.75. View

19.

Bikadi Z, Hazai E . Application of the PM6 semi-empirical method to modeling proteins enhances docking accuracy of AutoDock. J Cheminform. 2010; 1:15. PMC: 2820493. DOI: 10.1186/1758-2946-1-15. View

20.

Stark K, Dostalek M, Guengerich F . Expression and purification of orphan cytochrome P450 4X1 and oxidation of anandamide. FEBS J. 2008; 275(14):3706-17. PMC: 4765179. DOI: 10.1111/j.1742-4658.2008.06518.x. View